MicroRNA dysregulation in Alzheimer’s disease

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background and Objective: Alzheimer’s disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD. These miRNAs could play a significant role in the pathophysiology of AD, in both β-amyloid peptide and Tau toxicity. Conclusion: The identification of dysregulated miRNAs pattern can serve as specific AD biomarkers which may provide the basis for new and effective diagnostic approach. In addition, these miRNAs may represent new targets for pharmaceutical development.

Original languageEnglish
Pages (from-to)1000-1009
Number of pages10
JournalCNS and Neurological Disorders - Drug Targets
Volume16
Issue number9
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

MicroRNAs
Alzheimer Disease
Amyloid
Peptides
Neurodegenerative Diseases
Biomarkers
Delivery of Health Care
Pharmaceutical Preparations
Genes

Keywords

  • Alzheimer disease
  • Biomarker
  • MicroRNA
  • Tauopathy
  • Treatment
  • β-amyloid

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

MicroRNA dysregulation in Alzheimer’s disease. / Putteeraj, Manish; Yahaya, Mohamad Fairuz; Teoh, Seong Lin.

In: CNS and Neurological Disorders - Drug Targets, Vol. 16, No. 9, 01.12.2017, p. 1000-1009.

Research output: Contribution to journalReview article

@article{d309620a6e0342fab84efdc5d3d46449,
title = "MicroRNA dysregulation in Alzheimer’s disease",
abstract = "Background and Objective: Alzheimer’s disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD. These miRNAs could play a significant role in the pathophysiology of AD, in both β-amyloid peptide and Tau toxicity. Conclusion: The identification of dysregulated miRNAs pattern can serve as specific AD biomarkers which may provide the basis for new and effective diagnostic approach. In addition, these miRNAs may represent new targets for pharmaceutical development.",
keywords = "Alzheimer disease, Biomarker, MicroRNA, Tauopathy, Treatment, β-amyloid",
author = "Manish Putteeraj and Yahaya, {Mohamad Fairuz} and Teoh, {Seong Lin}",
year = "2017",
month = "12",
day = "1",
doi = "10.2174/1871527316666170807142311",
language = "English",
volume = "16",
pages = "1000--1009",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - MicroRNA dysregulation in Alzheimer’s disease

AU - Putteeraj, Manish

AU - Yahaya, Mohamad Fairuz

AU - Teoh, Seong Lin

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background and Objective: Alzheimer’s disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD. These miRNAs could play a significant role in the pathophysiology of AD, in both β-amyloid peptide and Tau toxicity. Conclusion: The identification of dysregulated miRNAs pattern can serve as specific AD biomarkers which may provide the basis for new and effective diagnostic approach. In addition, these miRNAs may represent new targets for pharmaceutical development.

AB - Background and Objective: Alzheimer’s disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD. These miRNAs could play a significant role in the pathophysiology of AD, in both β-amyloid peptide and Tau toxicity. Conclusion: The identification of dysregulated miRNAs pattern can serve as specific AD biomarkers which may provide the basis for new and effective diagnostic approach. In addition, these miRNAs may represent new targets for pharmaceutical development.

KW - Alzheimer disease

KW - Biomarker

KW - MicroRNA

KW - Tauopathy

KW - Treatment

KW - β-amyloid

UR - http://www.scopus.com/inward/record.url?scp=85040949515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040949515&partnerID=8YFLogxK

U2 - 10.2174/1871527316666170807142311

DO - 10.2174/1871527316666170807142311

M3 - Review article

C2 - 28782488

AN - SCOPUS:85040949515

VL - 16

SP - 1000

EP - 1009

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 9

ER -